Investor Presentaiton slide image

Investor Presentaiton

Bringing new cancer treatments to patients around the world Europe • Granted approval for KEYNOTE-091 for adjuvant treatment of certain patients with NSCLC • Granted approval for KEYNOTE-811 for 1L treatment of patients with certain gastric or gastroesophageal junction adenocarcinoma Japan • Received approval for Lynparza in combination with abiraterone and prednisone for treatment of certain adult patients with BRCA-mutated metastatic castration-resistant prostate cancer based on Phase 3 PROpel study 1. In collaboration with AstraZeneca MERCK 24
View entire presentation